Literature DB >> 8689941

Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe.

Z Zhang1, M J Fasco, Z Huang, F P Guengerich, L S Kaminsky.   

Abstract

Two forms of the cytochrome P450 enzyme superfamily, P4501A1 and P4501A2, that are heterogeneously distributed in populations and are induced in response to environmental factors are important because of their capacity to bioactivate procarcinogens. Phenotyping P4501A1 and P4501A2 in individuals will thus provide assessments of those individuals' susceptibility to procarcinogens. The anticoagulant drug warfarin is metabolized by human P4501A1 and P4501A2, and we have characterized this metabolism for the R-warfarin enantiomer as a potential in vivo probe. cDNA-expressed human P4501A1 and P4501A2 are regioselective for R-warfarin 6- and 8-hydroxylation with very similar KM values: 1.4 mM (6-hydroxylation), 1.2 mM (8-hydroxylation), 1.6 mM (6-hydroxylation), and 1.4 mM (8-hydroxylation), respectively, indicating possible binding competition for R-warfarin between the two forms. However, when comparing 6- and 8-hydroxylation, P4501A1 showed weak regioselectivity for 8-hydroxylation, whereas P4501A2 exhibited strong regioselectivity for 6-hydroxylation, with 6-hydroxylation/8-hydroxylation ratios of 0.6 and 5.0, respectively. These findings were confirmed by using microsomes from 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated HepG2 and MCF-7 cells expressing only P4501A1 (ratios of 0.7), and from human hepatic microsomal preparations containing only P4501A2 (average ratios of 4.0). P4501A2 levels in the liver preparations, as assessed by densitometry of immunoblots, correlated with R-warfarin 6-hydroxylation rates (r2 = 0.83) and caffeine 3-demethylation rates (r2 = 0.67), but not with R-warfarin 8-hydroxylation rates. P450s 2A6, 2B6, 2C9, 2D6, 2E1, and 3A4 did not yield either 6- or 8-hydroxy-warfarin from R-warfarin. We conclude that R-warfarin 6-hydroxylation rates are markers for human hepatic P4501A2, whereas ratios of 6-hydroxylation/8-hydroxylation could be used in vitro as a marker for P4501A1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8689941

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.

Authors:  Drew R Jones; So-Young Kim; Michael Guderyon; Chul-Ho Yun; Jeffery H Moran; Grover P Miller
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

2.  Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy.

Authors:  Dhakchinamoorthi Krishna Kumar; Deepak Gopal Shewade; Subramani Parasuraman; Sundaram Rajan; Jayaraman Balachander; B V Sai Chandran; Chandrasekaran Adithan
Journal:  J Young Pharm       Date:  2013-03-16

Review 3.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  In silico pharmacogenetics of warfarin metabolism.

Authors:  Yingying Guo; Paul Weller; Erin Farrell; Paul Cheung; Bill Fitch; Douglas Clark; Shao-yong Wu; Jianmei Wang; Guochun Liao; Zhaomei Zhang; John Allard; Janet Cheng; Anh Nguyen; Sharon Jiang; Steve Shafer; Jonathan Usuka; Mohammad Masjedizadeh; Gary Peltz
Journal:  Nat Biotechnol       Date:  2006-05       Impact factor: 54.908

5.  Warfarin dose related to apolipoprotein E (APOE) genotype.

Authors:  Hugo Kohnke; Kristina Sörlin; Göran Granath; Mia Wadelius
Journal:  Eur J Clin Pharmacol       Date:  2005-06-11       Impact factor: 2.953

Review 6.  Development and Uses of Offline and Web-Searchable Metabolism Databases - The Case of Benzo[a]pyrene.

Authors:  Slobodan P Rendic; Frederick P Guengerich
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

7.  Separation and determination of warfarin enantiomers in human plasma using a novel polymeric surfactant for micellar electrokinetic chromatography-mass spectrometry.

Authors:  Jingguo Hou; Jie Zheng; Shahab A Shamsi
Journal:  J Chromatogr A       Date:  2007-04-21       Impact factor: 4.759

Review 8.  Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Authors:  Mohamed H A Shahin; Julie A Johnson
Journal:  Curr Opin Cardiol       Date:  2013-05       Impact factor: 2.161

9.  Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins.

Authors:  So-Young Kim; Ji-Yeon Kang; Jessica H Hartman; Sun-Ha Park; Drew R Jones; Chul-Ho Yun; Gunnar Boysen; Grover P Miller
Journal:  Drug Metab Lett       Date:  2012-09-01

10.  Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans.

Authors:  Grover P Miller; Drew R Jones; Shane Z Sullivan; Anna Mazur; Suzanne N Owen; Neil C Mitchell; Anna Radominska-Pandya; Jeffery H Moran
Journal:  Chem Res Toxicol       Date:  2009-07       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.